WHO WE ARE
We are a clinical-stage medical device company developing a platform neuromodulation technology to treat diseases of undesired neural activity. Our initial indication is chronic pain.
Presidio Medical Announces $30 Million Financing Round Led by Invus Opportunities
SOUTH SAN FRANCISCO, Calif., July 14, 2020 – Presidio Medical, Inc., a clinical-stage medical device company developing a neuromodulation platform technology with an initial indication to treat chronic pain, today announced it has closed $30 million in financing. The financing round was led by Invus Opportunities, with participation from existing investor, Action Potential Venture Capital.LEARN MORE